CBX2 and ovarian carcinoma: Functional experiments also displayed that CBX2 overexpression restored the effects of miR-136 mimic on tumor progression and PTX sensitivity, which demonstrated that CBX2 acted as an oncogene and could inhibit PTX sensitivity in PTX-resistant ovarian cancer.